3d Porta Fortuna
-
ANNUNCIO: Segui le NewsLetter di Borse.it.
Al via la Newsletter di Borse, con tutte le notizie quotidiane sui mercati finanziari. Iscriviti per rimanere aggiornato con le ultime News di settore, quotazioni e titoli del momento.
Per iscriverti visita questo link.
aliex67
3 pesche al giorno..
- Registrato
- 9/5/02
- Messaggi
- 2.777
- Punti reazioni
- 89
aliex67
3 pesche al giorno..
- Registrato
- 9/5/02
- Messaggi
- 2.777
- Punti reazioni
- 89
se non li trovi eccoli qua !!!
Maggiori investitori istituzionali
Azionista Azioni % Az. Valore* Data operazione
SUNRISE PARTNERS, L.L.C. 3619683 3.57 $7890908 31-12-2005
Barclays Global Investors UK Holdings Ltd 2915247 2.88 $6355238 31-12-2005
LINDEN CAPITAL LP 2529487 2.50 $5514281 31-12-2005
VANGUARD GROUP, INC. (THE) 1077127 1.06 $2348136 31-12-2005
DIMENSIONAL FUND ADVISORS INC 1045287 1.03 $2278725 31-12-2005
STATE STREET CORPORATION 723559 .71 $1577358 31-12-2005
MORGAN STANLEY 697073 .69 $1519619 31-12-2005
NORTHERN TRUST CORPORATION 531782 .53 $1159284 31-12-2005
CITADEL LIMITED PARTNERSHIP 517165 .51 $1127419 31-12-2005
TIAA-CREF INVESTMENT MANAGEMENT, LLC 506318 .50 $1103773 31-12-2005
Maggiori fondi comuni istituzionali
Azionista Azioni % Az. Valore* Data operazione
ISHARES NASDAQ BIOTECHNOLOGY INDEX FUND 677983 .67 $1478002 31-12-2005
VANGUARD TOTAL STOCK MARKET INDEX FUND 572471 .57 $1247986 31-12-2005
DFA U.S. MICRO CAP PORTFOLIO 464929 .46 $976350 30-11-2005
ISHARES RUSSELL 2000 INDEX FD 429400 .42 $936092 31-12-2005
COLLEGE RETIREMENT EQUITIES FUND-STOCK ACCOUNT 387217 .38 $844133 31-12-2005
VANGUARD EXTENDED MARKET INDEX FUND 354647 .35 $773130 31-12-2005
ISHARES RUSSELL 2000 GROWTH INDEX FD 308752 .30 $673079 31-12-2005
DFA U.S. SMALL CAP SERIES 168900 .17 $354690 30-11-2005
PACIFIC SELECT FUND-SMALL CAP INDEX PORTFOLIO 68500 .07 $149330 31-12-2005
COLLEGE RETIREMENT EQUITIES FUND-SOCIAL CHOICE ACCOUNT 65817 .06 $143481 31-12-2005
Maggiori investitori istituzionali
Azionista Azioni % Az. Valore* Data operazione
SUNRISE PARTNERS, L.L.C. 3619683 3.57 $7890908 31-12-2005
Barclays Global Investors UK Holdings Ltd 2915247 2.88 $6355238 31-12-2005
LINDEN CAPITAL LP 2529487 2.50 $5514281 31-12-2005
VANGUARD GROUP, INC. (THE) 1077127 1.06 $2348136 31-12-2005
DIMENSIONAL FUND ADVISORS INC 1045287 1.03 $2278725 31-12-2005
STATE STREET CORPORATION 723559 .71 $1577358 31-12-2005
MORGAN STANLEY 697073 .69 $1519619 31-12-2005
NORTHERN TRUST CORPORATION 531782 .53 $1159284 31-12-2005
CITADEL LIMITED PARTNERSHIP 517165 .51 $1127419 31-12-2005
TIAA-CREF INVESTMENT MANAGEMENT, LLC 506318 .50 $1103773 31-12-2005
Maggiori fondi comuni istituzionali
Azionista Azioni % Az. Valore* Data operazione
ISHARES NASDAQ BIOTECHNOLOGY INDEX FUND 677983 .67 $1478002 31-12-2005
VANGUARD TOTAL STOCK MARKET INDEX FUND 572471 .57 $1247986 31-12-2005
DFA U.S. MICRO CAP PORTFOLIO 464929 .46 $976350 30-11-2005
ISHARES RUSSELL 2000 INDEX FD 429400 .42 $936092 31-12-2005
COLLEGE RETIREMENT EQUITIES FUND-STOCK ACCOUNT 387217 .38 $844133 31-12-2005
VANGUARD EXTENDED MARKET INDEX FUND 354647 .35 $773130 31-12-2005
ISHARES RUSSELL 2000 GROWTH INDEX FD 308752 .30 $673079 31-12-2005
DFA U.S. SMALL CAP SERIES 168900 .17 $354690 30-11-2005
PACIFIC SELECT FUND-SMALL CAP INDEX PORTFOLIO 68500 .07 $149330 31-12-2005
COLLEGE RETIREMENT EQUITIES FUND-SOCIAL CHOICE ACCOUNT 65817 .06 $143481 31-12-2005
Earth Simulator
Nuovo Utente
- Registrato
- 8/11/03
- Messaggi
- 1.687
- Punti reazioni
- 125
Ianuzzo ha scritto:
No, ti sbagli
Si continua a sperare, ...invece, sul alvoro di scienziati e tecnici. Che il loro impegno non risulti vano.Che riescano a trasformare una intelligente intuizione in una efficace cura
- Registrato
- 28/1/06
- Messaggi
- 1.808
- Punti reazioni
- 97
sento odor di pollo allo spiedo
buona giornata anche a voi
buona giornata anche a voi
silvio appiani
Nuovo Utente
- Registrato
- 31/1/06
- Messaggi
- 864
- Punti reazioni
- 62
Sui massimi di giornata
CELL THERAPEUTICS
ACQUISTO VENDITA
N. Offerte Q.tà DENARO LETTERA Q.tà N. Offerte
1 1500 1.472 1.474 865 1
1 10000 1.471 1.479 1700 1
1 500 1.47 1.48 10760 5
2 4300 1.466 1.481 1050 2
3 13800 1.465 1.482 9991 2
Ora Ultimo Diff.% Min Max Controvalore Tot.
14:57:40.08 1,474 3,149 1,433 1,48 1137789
CELL THERAPEUTICS
ACQUISTO VENDITA
N. Offerte Q.tà DENARO LETTERA Q.tà N. Offerte
1 1500 1.472 1.474 865 1
1 10000 1.471 1.479 1700 1
1 500 1.47 1.48 10760 5
2 4300 1.466 1.481 1050 2
3 13800 1.465 1.482 9991 2
Ora Ultimo Diff.% Min Max Controvalore Tot.
14:57:40.08 1,474 3,149 1,433 1,48 1137789
silvio appiani
Nuovo Utente
- Registrato
- 31/1/06
- Messaggi
- 864
- Punti reazioni
- 62
Vedo la Luce....................................................si è alzata la persiana chavallo67
Nuovo Utente
- Registrato
- 16/3/05
- Messaggi
- 12.572
- Punti reazioni
- 284
.. anche 'sta motizia non "c'entra" nulla con cell ..
<<< Enrollment Completed in Phase III Studies of Nexavar for Patients With Metastatic Melanoma and Liver Cancer
Wednesday May 3, 8:00 am ET
WEST HAVEN, Conn. and EMERYVILLE, Calif., May 3 /PRNewswire-FirstCall/ -- Bayer Pharmaceuticals Corporation (NYSE: BAY - News) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - News) today announced the completion of patient enrollment in two randomized, double-blind, Phase III clinical trials; one administering Nexavar® (sorafenib) tablets in combination with the chemotherapeutic agents carboplatin and paclitaxel in patients with advanced metastatic melanoma and another administering Nexavar as a single agent in patients with advanced hepatocellular carcinoma (HCC), or liver cancer.
ADVERTISEMENT
"Therapy with Nexavar could potentially provide an important advancement in the treatment of these difficult diseases, and we are pleased to have reached these milestones," said Henry Fuchs, M.D., executive vice president and chief medical officer of Onyx Pharmaceuticals. "While the studies are still ongoing and analyses will not commence until the pre-specified number of events are reached, we look forward to generating randomized data in these indications."
Trial Designs
The company-sponsored melanoma trial is designed to evaluate the safety and efficacy of Nexavar when co-administered with chemotherapy, and has progression-free survival as its primary endpoint. Approximately 250 patients with disease progression following one previous systemic chemotherapeutic treatment (with either dacarbazine (DTIC) or temozolomide) were enrolled into the study. In addition to a standard dosing schedule of carboplatin (AUC 6) and paclitaxel (225 mg/m2), patients were randomized to receive either 400 mg of Nexavar twice daily or matching placebo. The melanoma study includes sites in the Americas, Europe, and Australia.
The Phase III study in patients with advanced HCC is designed to measure differences in overall survival, time to symptom progression and time to tumor progression of Nexavar versus placebo. Approximately 560 patients who had not received previous systemic treatment for their disease were randomized to receive 400 mg of oral Nexavar twice daily or matching placebo. The HCC study is being conducted in the Americas, Europe, and Australia/New Zealand.
About Melanoma
Cancer of the skin (nonmelanoma and melanoma skin cancers combined) is the most common type of cancer, accounting for more than 50 percent of all cancers. In some parts of the world, especially among Western countries, melanoma is becoming more common every year. In the United States, for example, the percentage of people who develop melanoma has more than doubled in the past 20 years. Melanoma accounts for about four percent of skin cancer cases but causes about 79 percent of skin cancer deaths. In 2002, about 160,000 people worldwide (about 53,000 Americans) were diagnosed with melanoma, and more than 40,000 of them (about 7,500 Americans) died from the disease. For more information on melanoma, visit the Melanoma International Foundation (MIF) web site at: http://www.melanomainternational.org.
About Hepatocellular Carcinoma
Hepatocellular carcinoma, also known as primary liver cancer, is the most common form of liver cancer and is responsible for 80 percent of the primary malignant liver tumors in adults. It is the fifth most common cancer in the world. In 2002, approximately 626,000 HCC cases were reported worldwide, with 15,000 cases in the United States and 53,600 in Europe. HCC is most prevalent in developing countries, particularly in East and Southeast Asia, the Pacific Basin, and sub-Saharan Africa. Of the 626,000 cases worldwide, approximately 410,000 were reported in Eastern Asia (with 346,000 in China and 40,000 in Japan alone). HCC causes more than 600,000 deaths annually worldwide. The five-year relative survival rate is about seven percent.
About Nexavar
Nexavar is an oral multi-kinase inhibitor that targets both the tumor cell and tumor vasculature. In preclinical models, Nexavar targeted members of two classes of kinases known to be involved in both cell proliferation (growth) and angiogenesis (blood supply) - two important processes that enable cancer growth. These kinases included RAF kinase, VEGFR-2, VEGFR-3, PDGFR-B, KIT, and FLT-3.
Nexavar has been studied in more than 20 tumor types and in nearly 8,000 clinical trial patients. Nexavar is currently in Phase III clinical trials for the treatment of advanced hepatocellular carcinoma (HCC), or liver cancer, and metastatic melanoma, or skin cancer. A Phase III clinical trial in non-small cell lung cancer (NSCLC) was initiated in February 2006. In addition to company-sponsored trials, there are a variety of Nexavar studies being sponsored by government agencies, cooperative groups and individual investigators.
Important Safety Considerations for U.S. Patients Taking Nexavar
Based on the current, approved package insert for the treatment of patients with advanced kidney cancer, hypertension may occur early in the course of therapy and blood pressure should be monitored weekly during the first six weeks of therapy and treated as needed. Incidence of bleeding regardless of causality was 15% for Nexavar vs. 8% for placebo and the incidence of treatment-emergent cardiac ischemia/infarction was 2.9% for Nexavar vs. 0.4% for placebo. Most common treatment-emergent adverse events with Nexavar were diarrhea, rash/desquamation, fatigue, hand-foot skin reaction, alopecia, and nausea. Grade 3/4 adverse events were 38% for Nexavar vs. 28% for placebo. Women of child-bearing potential should be advised to avoid becoming pregnant and advised against breast-feeding. In cases of any severe or persistent side effects, temporary treatment interruption, dose modification or permanent discontinuation should be considered.
For U.S. Nexavar prescribing information, visit http://www.nexavar.com or call 1.866.NEXAVAR (1.866.639.2827).
About Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. is engaged in the development of novel cancer therapies that target the molecular basis of cancer. With its collaborators, the company is developing small molecule drugs, including Nexavar with Bayer Pharmaceuticals Corporation. For more information about Onyx's pipeline and activities, visit the company's web site at: http://www.onyx-pharm.com.>>>
!!~
<<< Enrollment Completed in Phase III Studies of Nexavar for Patients With Metastatic Melanoma and Liver Cancer
Wednesday May 3, 8:00 am ET
WEST HAVEN, Conn. and EMERYVILLE, Calif., May 3 /PRNewswire-FirstCall/ -- Bayer Pharmaceuticals Corporation (NYSE: BAY - News) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - News) today announced the completion of patient enrollment in two randomized, double-blind, Phase III clinical trials; one administering Nexavar® (sorafenib) tablets in combination with the chemotherapeutic agents carboplatin and paclitaxel in patients with advanced metastatic melanoma and another administering Nexavar as a single agent in patients with advanced hepatocellular carcinoma (HCC), or liver cancer.
ADVERTISEMENT
"Therapy with Nexavar could potentially provide an important advancement in the treatment of these difficult diseases, and we are pleased to have reached these milestones," said Henry Fuchs, M.D., executive vice president and chief medical officer of Onyx Pharmaceuticals. "While the studies are still ongoing and analyses will not commence until the pre-specified number of events are reached, we look forward to generating randomized data in these indications."
Trial Designs
The company-sponsored melanoma trial is designed to evaluate the safety and efficacy of Nexavar when co-administered with chemotherapy, and has progression-free survival as its primary endpoint. Approximately 250 patients with disease progression following one previous systemic chemotherapeutic treatment (with either dacarbazine (DTIC) or temozolomide) were enrolled into the study. In addition to a standard dosing schedule of carboplatin (AUC 6) and paclitaxel (225 mg/m2), patients were randomized to receive either 400 mg of Nexavar twice daily or matching placebo. The melanoma study includes sites in the Americas, Europe, and Australia.
The Phase III study in patients with advanced HCC is designed to measure differences in overall survival, time to symptom progression and time to tumor progression of Nexavar versus placebo. Approximately 560 patients who had not received previous systemic treatment for their disease were randomized to receive 400 mg of oral Nexavar twice daily or matching placebo. The HCC study is being conducted in the Americas, Europe, and Australia/New Zealand.
About Melanoma
Cancer of the skin (nonmelanoma and melanoma skin cancers combined) is the most common type of cancer, accounting for more than 50 percent of all cancers. In some parts of the world, especially among Western countries, melanoma is becoming more common every year. In the United States, for example, the percentage of people who develop melanoma has more than doubled in the past 20 years. Melanoma accounts for about four percent of skin cancer cases but causes about 79 percent of skin cancer deaths. In 2002, about 160,000 people worldwide (about 53,000 Americans) were diagnosed with melanoma, and more than 40,000 of them (about 7,500 Americans) died from the disease. For more information on melanoma, visit the Melanoma International Foundation (MIF) web site at: http://www.melanomainternational.org.
About Hepatocellular Carcinoma
Hepatocellular carcinoma, also known as primary liver cancer, is the most common form of liver cancer and is responsible for 80 percent of the primary malignant liver tumors in adults. It is the fifth most common cancer in the world. In 2002, approximately 626,000 HCC cases were reported worldwide, with 15,000 cases in the United States and 53,600 in Europe. HCC is most prevalent in developing countries, particularly in East and Southeast Asia, the Pacific Basin, and sub-Saharan Africa. Of the 626,000 cases worldwide, approximately 410,000 were reported in Eastern Asia (with 346,000 in China and 40,000 in Japan alone). HCC causes more than 600,000 deaths annually worldwide. The five-year relative survival rate is about seven percent.
About Nexavar
Nexavar is an oral multi-kinase inhibitor that targets both the tumor cell and tumor vasculature. In preclinical models, Nexavar targeted members of two classes of kinases known to be involved in both cell proliferation (growth) and angiogenesis (blood supply) - two important processes that enable cancer growth. These kinases included RAF kinase, VEGFR-2, VEGFR-3, PDGFR-B, KIT, and FLT-3.
Nexavar has been studied in more than 20 tumor types and in nearly 8,000 clinical trial patients. Nexavar is currently in Phase III clinical trials for the treatment of advanced hepatocellular carcinoma (HCC), or liver cancer, and metastatic melanoma, or skin cancer. A Phase III clinical trial in non-small cell lung cancer (NSCLC) was initiated in February 2006. In addition to company-sponsored trials, there are a variety of Nexavar studies being sponsored by government agencies, cooperative groups and individual investigators.
Important Safety Considerations for U.S. Patients Taking Nexavar
Based on the current, approved package insert for the treatment of patients with advanced kidney cancer, hypertension may occur early in the course of therapy and blood pressure should be monitored weekly during the first six weeks of therapy and treated as needed. Incidence of bleeding regardless of causality was 15% for Nexavar vs. 8% for placebo and the incidence of treatment-emergent cardiac ischemia/infarction was 2.9% for Nexavar vs. 0.4% for placebo. Most common treatment-emergent adverse events with Nexavar were diarrhea, rash/desquamation, fatigue, hand-foot skin reaction, alopecia, and nausea. Grade 3/4 adverse events were 38% for Nexavar vs. 28% for placebo. Women of child-bearing potential should be advised to avoid becoming pregnant and advised against breast-feeding. In cases of any severe or persistent side effects, temporary treatment interruption, dose modification or permanent discontinuation should be considered.
For U.S. Nexavar prescribing information, visit http://www.nexavar.com or call 1.866.NEXAVAR (1.866.639.2827).
About Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. is engaged in the development of novel cancer therapies that target the molecular basis of cancer. With its collaborators, the company is developing small molecule drugs, including Nexavar with Bayer Pharmaceuticals Corporation. For more information about Onyx's pipeline and activities, visit the company's web site at: http://www.onyx-pharm.com.>>>
!!~